PharmaPoint: Psoriasis – Global Drug Forecast and Market Analysis to 2024

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$10995
Buy Report View Sample

Published: April 01, 2016 Report Code: GDHC119PIDR-ST

Select Item

Psoriasis (PsO) is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide. Specifically, adult plaque psoriasis, the most common form of Psoriasis, is the focus of this report. Although not life-threatening, Psoriasis causes tremendous morbidity and personal angst for patients.

GlobalData projects the psoriasis market in 8MM to experience modest growth during the forecast period at a CAGR of 7.26%. This growth will be driven primarily by the highly anticipated arrivals of promising systemic therapies- interleukin-23 (IL-23) inhibitors (guselkumab and tildrakizumab), interleukin-17 (IL-17) inhibitors (Cosentyx, Taltz, and brodalumab) as well as phsophodiesterase (PDE4) inhibitor- Otezla (apremilast). Nevertheless, looming patent expiries of high-grossing branded drugs- especially TNF inhibitors, Humira, Enbrel and Remicade, in the US, 5EU (France, Germany, Italy, Spain, UK), and Japan, along with rapid global developments of biosimilars , are expected to spread the growth throughout the different classes of products, away from the branded TNF inhibitors which have traditionally been the main driver of growth in the prior years.

Scope

Overview of Psoriasis, including epidemiology, etiology, pathophysiology, symptoms and current treatment options

Topline Psoriasis market revenue from 2014–2024. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.

Key topics covered include strategic competitor assessment, unmet needs, pipeline assessment, and market outlook for the Psoriasis market.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products- including promising IL-17 and IL-23 inhibitors.

Analysis of the current and future market competition in the global Psoriasis market (8MM). Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

How good is the management of Psoriasis with marketed therapies?

Which drugs and players are important in the current management landscape?

What are the most promising late-stage pipeline drugs and how will their launch shape the future treatment landscape in the Psoriasis market?

What are the significant unmet needs and remaining opportunities in the Psoriasis market?

What clinical and commercial factors are likely to uptake of Psoriasis therapies in the US, 5EU, Japan and India?

Amgen
AbbVie
Can-Fite Biopharma
Celgene
Eli Lilly
Johnson & Johnson
LEO Pharma
Merck
Novartis
Pfizer

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures

2Introduction

2.1Catalyst

2.2Related Reports

2.3Upcoming Related Reports

3Disease Overview

3.1Etiology and Pathophysiology

3.1.1Etiology

3.1.2Pathophysiology

3.2Symptoms

4Epidemiology

4.1Disease Background

4.2Risk Factors and Comorbidities

4.3Global Trends

4.3.1Prevalence

4.4Forecast Methodology

4.4.1Sources Used for One-Year Diagnosed Prevalence of Psoriasis

4.4.2Sources Not Used

4.4.3Forecast Assumptions and Methods, One-Year Diagnosed Prevalent Cases of Psoriasis

4.5Epidemiological Forecast for Psoriasis (2014–2024)

4.5.1One-Year Diagnosed Prevalent Cases of Psoriasis

4.5.2Age-Specific One-Year Diagnosed Prevalent Cases of Psoriasis

4.5.3Sex-Specific One-Year Diagnosed Prevalent Cases of Psoriasis

4.5.4Age-Standardized One-Year Diagnosed Prevalent Cases of Psoriasis

4.5.5One-Year Diagnosed Prevalent Cases of Psoriasis by Severity

4.6Discussion

4.6.1Epidemiological Forecast Insight

4.6.2Limitations of the Analysis

4.6.3Strengths of the Analysis

5Disease Management

5.1Diagnosis and Treatment Overview

5.1.1Diagnosis

5.1.2Leading Prescribed Drugs and Treatment Guidelines

5.1.3Clinical Practice

5.2US

5.35EU

5.4Japan

5.5India

6Competitive Assessment

6.1Overview

6.2Strategic Competitor Assessment

6.3Product Profiles – Major Brands

6.3.1Enbrel (Etanercept)

6.3.2Humira (Adalimumab)

6.3.3Remicade (Infliximab)

6.3.4Stelara (Ustekinumab)

6.3.5Cosentyx (Secukinumab)

6.3.6Taltz (Ixekizumab)

6.3.7Otezla (Apremilast)

6.3.8Taclonex and Enstilar (Calcipotriene and Betamethasone Dipropionate)

6.3.9Methotrexate

6.3.10Fumaderm (Fumaric Acid Esters)

6.3.11Alzumab (Itolizumab)

6.3.12Other Therapeutic Drug Classes Used in Psoriasis

6.3.13Non-pharmacological Therapy

7Unmet Need and Opportunity

7.1Overview

7.2Limited Patient Access Due to Drug Reimbursement Pattern

7.2.1Unmet Need

7.2.2Gap Analysis

7.2.3Opportunity

7.3Improved Drug Safety and Efficacy Profiles

7.3.1Unmet Need

7.3.2Gap Analysis

7.3.3Opportunity

7.4Education and Treatment of Psychological Factors Accompanying Psoriasis

7.4.1Unmet Need

7.4.2Gap Analysis

7.4.3Opportunity

7.5Physician Education About the Different Types of Psoriasis, not Just Plaque Psoriasis

7.5.1Unmet Need

7.5.2Gap Analysis

7.5.3Opportunity

8Pipeline Assessment

8.1Overview

8.2Clinical Trial Mapping

8.2.1Clinical Trials by Country

8.3Clinical Trials by Phase and Trial Status

8.4Promising Drugs in Clinical Development

8.4.1Xeljanz (Tofacitinib)

8.4.2Brodalumab

8.4.3Guselkumab (CNTO-1959)

8.4.4Tildrakizumab

8.4.5Piclidenoson (CF-101)

8.4.6Additional Phase III Pipeline Products

8.4.7Phase II Pipeline Products

8.4.8Phase I Pipeline Products

8.5Biosimilar Pipeline Products

8.5.1Introduction

8.5.2Hospira’s Inflectra Versus J&J’s Remicade in Key Autoimmune Diseases

8.5.3Biosimilars in the Immunology Community

8.5.4By the Numbers: Biosimilars in Development

8.5.5The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry

8.5.6Uptake of Biosimilars for Psoriasis is Expected to Vary by Market

8.5.7Biosimilars Forecast

9Current and Future Players

9.1Overview

9.2Trends in Corporate Strategy

9.3Company Profiles

9.3.1Johnson & Johnson

9.3.2AbbVie

9.3.3Amgen

9.3.4Novartis

9.3.5Pfizer

9.3.6Eli Lilly

9.3.7Merck

9.3.8LEO Pharma

9.3.9Celgene

9.3.10Can-Fite Biopharma

10Market Outlook

10.1Global Markets

10.1.1Forecast

10.1.2Drivers and Barriers – Global Issues

10.2US

10.2.1Forecast

10.2.2Key Events

10.2.3Drivers and Barriers

10.35EU

10.3.1Forecast

10.3.2Key Events

10.3.3Drivers and Barriers

10.4Japan

10.4.1Forecast

10.4.2Key Events

10.4.3Drivers and Barriers

10.5India

10.5.1Forecast

10.5.2Key Events

10.5.3Drivers and Barriers

11Appendix

11.1Bibliography

11.2Abbreviations

11.3Methodology

11.4Forecasting Methodology

11.4.1Diagnosed Psoriasis Patients

11.4.2Percent Drug-Treated Patients

11.4.3Drugs Included in Each Therapeutic Class

11.4.4Launch and Patent Expiry Dates

11.4.5General Pricing Assumptions

11.4.6Individual Drug Assumptions

11.4.7Generic Erosion

11.4.8Pricing of Pipeline agents

11.5Physicians and Specialists Included in this Study

11.6Primary Research – Prescriber Survey

11.7About the Authors

11.7.1Author

11.7.2Reviewer

11.7.3Epidemiologist

11.7.4Global Director of Therapy Analysis and Epidemiology

11.7.5Global Head of Healthcare

11.8About GlobalData

11.9Contact Us

11.10Disclaimer

Table

Table 1: Immune Cells Involved in Lesions

Table 2: Symptoms of Psoriasis

Table 3: Risk Factors and Comorbidities for Psoriasis

Table 4: 8MM, Global Trends for the Diagnosed Prevalence of Psoriasis

Table 5: 8MM, Sources of Epidemiological Data Used for the Forecast for Psoriasis One-Year Diagnosed Prevalent Cases

Table 6: 8MM, Sources of Epidemiological Data Used for the Segmentation of One-Year Diagnosed Prevalent Cases of Psoriasis by Severity

Table 7: 8MM, One-Year Diagnosed Prevalent Cases of Psoriasis, Both Sexes, All Ages, N, 2014–2024

Table 8: 8MM, Age-Specific One-Year Diagnosed Prevalent Cases of Psoriasis, Both Sexes, N (Row %), 2014

Table 9: 8MM, Sex-Specific One-Year Diagnosed Prevalent Cases of Psoriasis, All Ages, N (Row %), 2014

Table 10: Minimal Investigative Measures Required Before Prescribing Biologics for Psoriasis

Table 11: Top Three Biologics Prescribed for Moderate to Severe Psoriasis by Market, 2014

Table 12: Treatment Guidelines for Psoriasis

Table 13: Country Profile – US

Table 14: Country Profile – 5EU

Table 15: Country Profile – Japan

Table 16: Country Profile – India

Table 17: Leading Treatments for Psoriasis, 2015

Table 18: Product Profile – Enbrel

Table 19: Enbrel Pivotal Study I Outcomes at 3 and 6 Months

Table 20: Enbrel pivotal study II outcomes at 3 Months

Table 21: Long-Term Studies on Enbrel Efficacy in Treatment of Psoriasis

Table 22: Long-Term Safety Profile of Enbrel in the Treatment of Psoriasis

Table 23: Enbrel SWOT Analysis, 2015

Table 24: Global Sales Forecast ($m) for Enbrel, 2014–2024

Table 25: Product Profile – Humira

Table 26: Humira pivotal study outcomes at 16 weeks

Table 27: Humira SWOT Analysis, 2015

Table 28: Global Sales Forecast ($m) for Humira, 2014–2024

Table 29: Product Profile – Remicade

Table 30: Efficacy Results of RESTORE1 Trial of Remicade vs. MTX at Week 26

Table 31: Safety Results and AEs of RESTORE1 Trial of Remicade vs. MTX at Week 16

Table 32: Remicade SWOT Analysis, 2015

Table 33: Global Sales Forecast ($m) for Remicade, 2014–2024

Table 34: Product Profile – Stelara

Table 35: Stelara Pivotal Study Outcomes at Week 12

Table 36: Stelara SWOT Analysis, 2015

Table 37: Global Sales Forecast ($m) for Stelara, 2014–2024

Table 38: Product Profile – Cosentyx

Table 39: Efficacy Endpoints in Cosentyx Phase III ERASURE Study

Table 40: Efficacy End Points in Cosentyx Phase III FIXTURE study

Table 41: Cosentyx SWOT Analysis, 2015

Table 42: Global Sales Forecast ($m) for Cosentyx, 2014–2024

Table 43: Product Profile – Taltz

Table 44: Efficacy Results of UNCOVER-2 at Week 12

Table 45: Efficacy Results of UNCOVER-3 at Week 12

Table 46: Taltz SWOT Analysis, 2015

Table 47: Global Sales Forecast ($m) for Taltz, 2014–2024

Table 48: Product Profile – Otezla

Table 49: Otezla Efficacy Results at Week 16 in Studies ESTEEM-1 and ESTEEM-2

Table 50: Otezla SWOT Analysis, 2015

Table 51: Global Sales Forecast ($m) for Otezla, 2014–2024

Table 52: Product Profile – Taclonex/Enstilar

Table 53: Taclonex Efficacy Outcomes from Pivotal Phase III Studies for Adult Scalp and Body Psoriasis.

Table 54: Taclonex/Enstilar SWOT Analysis, 2015

Table 55: Global Sales Forecast ($m) for Taclonex/Daivobet/Dovobet, 2014–2024

Table 56: Product Profile – Methotrexate

Table 57: Methotrexate SWOT Analysis, 2015

Table 58: Global Sales Forecast ($m) for Methotrexate, 2014–2024

Table 59: Product Profile – Fumaderm

Table 60: Fumaderm SWOT Analysis, 2015

Table 61: Global Sales Forecast ($m) for Fumaderm, 2014–2024

Table 62: Product Profile – Alzumab

Table 63: Alzumab SWOT Analysis, 2013

Table 64: Global Sales Forecast ($m) for Alzumab, 2014–2024

Table 65: Summary of Minor Therapeutic Drug Classes for Psoriasis, 2015

Table 66: Dosing Guidelines for Broadband Ultraviolet B

Table 67: Dosing Guidelines for Narrowband Ultraviolet B

Table 68: Overall Unmet Needs in Psoriasis – Current Level of Attainment

Table 69: Psoriasis – Clinical Trials by Phase and Status, 2015

Table 70: Psoriasis – Phase Pipeline, 2015

Table 71: Comparison of Therapeutic Classes in Development for Psoriasis, 2015

Table 72: Product Profile – Xeljanz

Table 73: Xeljanz SWOT Analysis, 2015

Table 74: Global Sales Forecast ($m) for Xeljanz, 2014–2024

Table 75: Product Profile – Brodalumab

Table 76: Brodalumab SWOT Analysis, 2015

Table 77: Global Sales Forecast ($m) for Brodalumab, 2014–2024

Table 78: Product Profile – Guselkumab

Table 79: Guselkumab SWOT Analysis, 2015

Table 80: Global Sales Forecast ($m) for Guselkumab, 2014–2024

Table 81: Product Profile – Tildrakizumab

Table 82: Tildrakizumab SWOT Analysis, 2015

Table 83: Global Sales Forecast ($m) for Tildrakizumab, 2014–2024

Table 84: Product Profile – Piclidenoson (CF-101)

Table 85: Piclidenoson SWOT Analysis, 2015

Table 86: Additional Phase III Psoriasis Pipeline drugs, 2015

Table 87: Phase II Psoriasis Pipeline, 2015

Table 88: Phase I Psoriasis Pipeline, 2015

Table 89: Marketed and Pipeline Biosimilars for Psoriasis in the 8MM, 2015

Table 90: Physician Uptake of Biosimilar Products for Psoriasis Across the 8MM, 2015

Table 91: Global Sales Forecast ($m) for Etanercept Biosimilars, 2014–2024

Table 92: Global Sales Forecast ($m) for Adalimumab Biosimilars, 2014–2024

Table 93: Global Sales Forecast ($m) for Infliximab Biosimilars, 2014–2024

Table 94: Key Companies in the Psoriasis Market, 2015

Table 95: J&J’s Psoriasis Portfolio Assessment, 2015

Table 96: J&J’s Psoriasis Portfolio SWOT Analysis, 2015

Table 97: AbbVie’s Psoriasis Portfolio Assessment, 2015

Table 98: AbbVie’s Psoriasis SWOT Analysis, 2015

Table 99: Amgen’s Psoriasis Portfolio Assessment, 2015

Table 100: Amgen’s Psoriasis SWOT Analysis, 2015

Table 101: Novartis’s Psoriasis Portfolio Assessment, 2015

Table 102: Novartis’ Psoriasis SWOT Analysis, 2015

Table 103: Pfizer’s Psoriasis Portfolio Assessment, 2015

Table 104: Pfizer’s Psoriasis Portfolio SWOT Analysis, 2015

Table 105: Eli Lilly’s Psoriasis Portfolio Assessment, 2015

Table 106: Eli Lilly’s Psoriasis Portfolio SWOT Analysis, 2015

Table 107: Merck’s Psoriasis Portfolio Assessment, 2015

Table 108: Merck’s Psoriasis Portfolio SWOT Analysis, 2015

Table 109: LEO Pharma’s Psoriasis Portfolio Assessment, 2015

Table 110: LEO Pharma’s Psoriasis Portfolio SWOT Analysis, 2015

Table 111: Celgene’s Psoriasis Portfolio Assessment, 2015

Table 112: Celgene’s Psoriasis Portfolio SWOT Analysis, 2015

Table 113: Can-Fite’s Psoriasis Portfolio Assessment, 2015

Table 114: Celgene’s Psoriasis Portfolio SWOT Analysis, 2015

Table 115: Global Sales Forecast ($m) for Psoriasis, 2014–2024

Table 116: Global Psoriasis Market – Drivers and Barriers, 2014–2024

Table 117: Sales Forecast ($) for Psoriasis in the US, 2014–2024

Table 118: Key Events Impacting Sales for Psoriasis in the US, 2014–2024

Table 119: Psoriasis Market in the US – Drivers and Barriers, 2014–2024

Table 120: Sales Forecast ($) for Psoriasis in the 5EU, 2014–2024

Table 121: Key Events Impacting Sales for Psoriasis in the 5EU, 2014–2024

Table 122: Psoriasis Market in the 5EU – Drivers and Barriers, 2014–2024

Table 123: Sales Forecast ($) for Psoriasis in Japan, 2014–2024

Table 124: Key Events Impacting Sales for Psoriasis in Japan, 2014–2024

Table 125: Psoriasis Market in Japan – Drivers and Barriers, 2014–2024

Table 126: Sales Forecast ($) for Psoriasis in India, 2014–2024

Table 127: Key Events Impacting Sales for Psoriasis in India, 2014–2024

Table 128: Psoriasis Market in India – Drivers and Barriers, 2014–2024

Table 129: Key Launch Dates

Table 130: Key Patent Expiries

Table 131: Key Launch Dates

Table 132: Physicians Surveyed, by Country

Figures

Figure 1: Psoriatic Plaque on Elbow of Patient

Figure 2: The Three Layers of the Skin and Associated Structures

Figure 3: Healthy Skin Versus Psoriatic Skin

Figure 4: 8MM, One-Year Diagnosed Prevalent Cases of Psoriasis, Both Sexes, All Ages, N, 2014–2024

Figure 5: 8MM, Age-Specific One-Year Diagnosed Prevalent Cases of Psoriasis, Both Sexes, N, 2014

Figure 6: 8MM, Sex-Specific One-Year Diagnosed Prevalent Cases of Psoriasis, All Ages, N, 2014

Figure 7: 8MM, Age-Standardized One-Year Diagnosed Prevalent Cases of Psoriasis (%), All Ages, by Sex, 2014

Figure 8: 8MM, Severity Profile of One-Year Diagnosed Prevalent Cases of Psoriasis, All Ages, Both Sexes, N, 2014

Figure 9: Psoriasis Therapeutics – Ongoing Clinical Trial Sites by Country, 2015

Figure 10: Competitive Assessment of Late-Stage Pipeline Agents in Psoriasis, 2014–2024

Figure 11: Biosimilar Prescribing Habits in Psoriasis Across the 8MM, 2015

Figure 12: Global Sales Forecast ($m) for Enbrel vs. Etanercept Biosimilars, 2014–2024

Figure 13: Global Sales Forecast ($m) for Humira vs. Adalimumab Biosimilars, 2014–2024

Figure 14: Global Sales Forecast ($m) for Remicade vs. Infliximab Biosimilars, 2014–2024

Figure 15: Company Portfolio Gap Analysis in Psoriasis, 2014–2024

Figure 16: Global Sales for Psoriasis by Region, 2014–2024

Figure 17: Sales for Psoriasis in the US by Drug Class, 2014–2024

Figure 18: Sales for Psoriasis in the 5EU by Drug Class, 2014–2024

Figure 19: Sales for Psoriasis in the 5EU by Region, 2014–2024

Figure 20: Sales for Psoriasis in Japan by Drug Class, 2014–2024

Figure 21: Sales for Psoriasis in India by Drug Class, 2014–2024

Frequently asked questions

PharmaPoint: Psoriasis – Global Drug Forecast and Market Analysis to 2024 standard reports
Currency USD
$10,995

Can be used by individual purchaser only

Most Popular
$21,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$32,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

PharmaPoint: Psoriasis – Global Drug Forecast and Market Analysis to 2024 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Immunology reports
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Pharmaceuticals
New
Clinical Trials Scorecard for Investigations in 2023
$695 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at PharmaPoint: Psoriasis – Global Drug Forecast and Market Analysis to 2024 in real time.

  • Access a live PharmaPoint: Psoriasis – Global Drug Forecast and Market Analysis to 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more